Reengineering red blood cells for cellular therapeutics and diagnostics

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Hematology

Background:

• Optimized technologies allow reversible nanopore creation in red blood cell membranes.
• This enables the reengineering of human erythrocytes for diverse biomedical uses.

Purpose of the Study:

• To review key advancements in erythrocyte reengineering for therapeutic and diagnostic applications.
• To highlight features crucial for advancing these technologies toward clinical approval.

Main Methods:

• Exploitation of engineered erythrocytes for controlled drug release, acting as bioreactors, drug targeting, and diagnostic imaging carriers.
• Utilizing animal models for preclinical development and adapting encapsulation procedures.
• Summarizing critical features enabling regulatory clinical approval.

Main Results:

• Engineered erythrocytes show promise in drug delivery, metabolic detoxification, targeted delivery, and diagnostics.
• Successful in vitro and preclinical studies have led to pilot clinical investigations.
• Industrialization of loading technologies and clinical development programs are underway.

Conclusions:

• Erythrocyte reengineering offers a novel therapeutic modality for patients with limited treatment options.
• Advancements in technology and preclinical success are driving progress toward clinical application and regulatory approval.